Newsroom
April 10, 2024
According to the National Cancer Institute, more than 3 million men are living with prostate cancer in the United States. Of those, survivorship after five years is 97 percent. With patients living longer and physicians seeing younger patients with this type of cancer, learning the best ways to treat patients and providing a better […]
February 22, 2024
The University of Texas Health Science Center at San Antonio (also called UT Health San Antonio) received $131.5 million in National Institutes of Health funding in federal fiscal year 2023, according to the Blue Ridge Institute for Medical Research. The university ranked No. 72 out of the 2,886 public and private institutions that received […]
October 18, 2023
Zhijie Liu, PhD, Department of Molecular Medicine, and CPRIT Scholar in Cancer Research at the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, was quoted in this story. Read More
October 6, 2023
The University of Texas Health Science Center at San Antonio (UT Health San Antonio) announces the successful launch of Pluvicto, a radiopharmaceutical used to treat patients with advanced metastatic prostate cancer. Approved by the U.S. Food and Drug Administration in March of 2022, Pluvicto is a novel targeted molecular therapy that delivers radiation treatment […]
October 5, 2023
Research led by Mays Cancer Center at The University of Texas Health Science Center at San Antonio has discovered that altering certain molecular interactions could yield new strategies for treating prostate cancer and related diseases. The study focuses on androgen receptors (AR), which are protein molecules that help direct the development of male sexual characteristics, […]
September 22, 2023
Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, introduces the newest technology in treating prostate cancer. This innovative method is called stereotactic body radiation therapy (SBRT), a minimally invasive therapy using high amounts of radiation with millimeter precision to destroy tumors in the prostate. Stereotactic body radiation therapy is a […]
